Liver fibrosis attributed to lipid lowering medications: two cases

被引：24

作者：

Punthakee, Z

Scully, LJ

Guindi, MM

Ooi, TC

机构：

[1] Univ Ottawa, Ottawa Hosp, Div Endocrinol & Metab, Ottawa, ON K1Y 4E9, Canada

[2] Univ Ottawa, Ottawa Hosp, Dept Med, Ottawa, ON K1Y 4E9, Canada

[3] Univ Ottawa, Ottawa Hosp, Div Gastroenterol, Ottawa, ON K1Y 4E9, Canada

[4] Univ Ottawa, Ottawa Hosp, Dept Pathol & Lab Med, Ottawa, ON K1Y 4E9, Canada

来源：

JOURNAL OF INTERNAL MEDICINE | 2001年 / 250卷 / 03期

关键词：

adverse effects; anticholesteremic agents; fibric acid derivatives; fibrosis; HMG-CoA reductase inhibitors; liver diseases;

D O I：

10.1046/j.1365-2796.2001.00848.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We identified two cases of chronic active hepatitis with liver fibrosis induced by lipid lowering drugs of the statin and fibrate classes despite regular monitoring of transaminases. There are few reports of clinically significant hepatitis induced by these drugs and even fewer cases of fibrosis. Given the growing use of these drugs, there are implications for monitoring patients on long-term therapy for liver damage.

引用

页码：249 / 254

页数：6

共 19 条

[1]

Ballare M, 1992, Minerva Gastroenterol Dietol, V38, P41

[2]

BALLARE M, 1991, Recenti Progressi in Medicina, V82, P233

[3]

BENICHOU C, 1990, J HEPATOL, V11, P272

[4]

BERNARD PH, 1994, GASTROEN CLIN BIOL, V18, P1048

[5]

CARRASCO JCG, 1996, MED CLIN, V14, P577

[6]

CHATRENET P, 1993, GASTROEN CLIN BIOL, V17, P612

[7]

Dumortier J, 1999, GASTROEN CLIN BIOL, V23, P1399

[8]

FEYDY P, 1991, GASTROEN CLIN BIOL, V15, P94

[9]

Ganne-Carrie N, 1998, GASTROEN CLIN BIOL, V22, P525

[10] ACUTE HEPATITIS INDUCED BY HMG-COA REDUCTASE INHIBITOR, LOVASTATIN [J].

GRIMBERT, S ;

PESSAYRE, D ;

DEGOTT, C ;

BENHAMOU, JP .

DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (09) :2032-2033

← 1 2 →